NCT05837689 is a retrospective observational study in pediatric B‑cell precursor ALL assessing blinatumomab used as consolidation in patients who are MRD‑positive by next‑generation sequencing (NGS). Intervention: Blinatumomab (IV), a bispecific T‑cell engager (BiTE) antibody construct. Mechanism of action: binds CD19 on B‑lineage leukemia cells and CD3 on T cells, redirecting endogenous T cells to eliminate CD19+ blasts via immune‑synapse formation and perforin/granzyme‑mediated cytotoxicity, with cytokine‑driven T‑cell activation/proliferation. Targets: CD19+ B‑cell precursor leukemic cells, T‑cell receptor/CD3 signaling and cytotoxic effector pathways. Primary focus: efficacy of MRD clearance as quantified by NGS.